Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mucosal melanoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Mucosal melanoma. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-002073-22 Sponsor Protocol Number: 11_DOG12_56 Start Date*: 2015-07-28
    Sponsor Name:The Christie NHS Foundation Trust, R&D
    Full Title: A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma( PIANO)
    Medical condition: In a subset of patients with advanced acral and mucosal melanoma exhibiting Tyrosine Kinase Receptor gene(c-KIT) mutation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000589 Acral lentiginous melanoma stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025667 Malignant melanoma site/stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000583 Acral lentiginous melanoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-004003-39 Sponsor Protocol Number: 2018-BN-001 Start Date*: 2018-12-19
    Sponsor Name:UZ Brussel
    Full Title: A stratified dual-arm open-label two-stage phase 2 trial of trametinib in patients with advanced pretreated BRAFV600 wild-type melanoma
    Medical condition: ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027150 Melanoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003380-95 Sponsor Protocol Number: CDYP688A12101 Start Date*: 2022-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
    Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) NO (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012945-49 Sponsor Protocol Number: ICR-CTSU/2009/10020 Start Date*: 2009-11-20
    Sponsor Name:Royal Marsden Hosptial Foundation Trust [...]
    1. Royal Marsden Hosptial Foundation Trust
    2. The Institute of Cancer Research
    Full Title: A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM)
    Medical condition: c-KIT mutated advanced acral or mucosal melanoma
    Disease: Version SOC Term Classification Code Term Level
    10 10025654 Malignant melanoma of sites other than skin LLT
    10 10000583 Acral lentiginous melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003921-51 Sponsor Protocol Number: BOT112-03 Start Date*: 2021-02-11
    Sponsor Name:Highlight Therapeutics
    Full Title: Phase 2 single arm clinical study to evaluate the efficacy and safety of intratumoral administration of BO-112 in combination with pembrolizumab in subjects that have progressed on anti-PD-1-based ...
    Medical condition: Advanced melanoma after progression to immunotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027155 Melanoma skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001925-15 Sponsor Protocol Number: ISS20159321 Start Date*: 2018-10-22
    Sponsor Name:Alcedis GmbH
    Full Title: Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant me...
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001557-31 Sponsor Protocol Number: ALKS4230-006 Start Date*: 2022-01-31
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients Wi...
    Medical condition: Advanced cutaneous melanoma and Advanced mucosal melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001628-23 Sponsor Protocol Number: 2017/2558 Start Date*: 2017-10-17
    Sponsor Name:Gustave Roussy
    Full Title: Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable h...
    Medical condition: Resectable head and neck mucosal melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005569-10 Sponsor Protocol Number: Bottom_2012 Start Date*: 2013-08-19
    Sponsor Name:University Hospital Essen
    Full Title: Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastati...
    Medical condition: Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic), and determined to be BRAF V600 mutation-positive
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001773-24 Sponsor Protocol Number: GO40558 Start Date*: 2019-12-05
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED M...
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001722-21 Sponsor Protocol Number: D533AC00001 Start Date*: 2022-03-08
    Sponsor Name:AstraZeneca AB
    Full Title: MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance ...
    Medical condition: Unresectable or Advanced Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002172-40 Sponsor Protocol Number: IEO838 Start Date*: 2019-01-23
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Primary Ipilimumab and Nivolumab combo-immunotherapy followed by adjuvant Nivolumab in locally advanced or limited metastatic melanoma.
    Medical condition: Patients with histologically or cytologically confirmed AJCC (8th ed.) Stage IIIB -IV resectable melanoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004453-23 Sponsor Protocol Number: R3767-ONC-2011 Start Date*: 2022-08-30
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
    Medical condition: Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002827-15 Sponsor Protocol Number: A3671009 Start Date*: 2006-01-19
    Sponsor Name:Pfizer Ltd. [...]
    1. Pfizer Ltd.
    2.
    Full Title: Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) BE (Completed) SE (Completed) GR (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) DE (Completed) GR (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000681-55 Sponsor Protocol Number: 3475-022 Start Date*: 2015-10-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma
    Medical condition: advanced or metastatic melanoma - all parts of the trial advanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001230-34 Sponsor Protocol Number: CA209-76K Start Date*: 2019-08-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb ...
    Medical condition: Completely resected Stage IIb/c melanoma subjects.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) CZ (Ongoing) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) Outside EU/EEA RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002408-15 Sponsor Protocol Number: Ipi4 Start Date*: 2013-11-05
    Sponsor Name:Oslo University Hospital
    Full Title: Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma
    Medical condition: Patients diagnosed with unresectable or metastatic melanoma, cutaneous, ocular, mucosal and unknown primary tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004501-24 Sponsor Protocol Number: CT-2011-01 Start Date*: 2012-03-06
    Sponsor Name:CureTech Ltd.
    Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002971-12 Sponsor Protocol Number: IMCgp100-201 Start Date*: 2016-05-26
    Sponsor Name:Immunocore Limited
    Full Title: A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compa...
    Medical condition: Advanced Malignant Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 13:40:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA